GlassScriptPhysician profile
Joseph K Postma
NPI 1962790170
$1,046.87
in general payments reported to CMS, 2019-2025
17 companies · $96.90 in 2025
The $96.90 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.49 · 2020: $22.19 · 2021: $23.89 · 2023: $14.79 · 2024: $832 · 2025: $96.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $943.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $206.51 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $172.94 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.17 | 2024 | Jardiance |
| Lilly USA, LLC | $102.75 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Janssen Pharmaceuticals, INC | $91.88 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $65.21 | 2024 | |
| Antares Pharma, INC. | $54.76 | 2024 | Xyosted |
| Madrigal Pharmaceuticals | $46.64 | 2024-2025 | Resmetirom, Rezdiffra |
| Neurocrine Biosciences, INC. | $36.35 | 2024-2025 | |
| Corcept Therapeutics | $31.97 | 2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $23.50 | 2024 | Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $19.97 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Astellas Pharma US INC | $18.91 | 2024 | Veozah |
| Amgen INC. | $18.15 | 2024 | Evenity, Prolia |
| Ibsa Pharma INC. | $15.68 | 2024 | Tirosint, Licart |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $14.79 | 2023 | Nexletol, Nexlizet, Contrave |
| E.R. Squibb & Sons, L.L.C. | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Postma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.